CD274 and non-small cell lung carcinoma: However, the incidence of MSI-H in non-small cell lung cancer (NSCLC) patients is exceedingly low (3), and the predictive value of PD-L1 expression and high TMB for neoadjuvant immunotherapy in NSCLC is highly debated (4, 5).